Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
The purpose of this study is to find the highest dose of the investigational immunotherapy 2141-V11 that can be given safely in people with bladder cancer that has not invaded the bladder muscle wall, has come back after BCG therapy, and will not be surgically removed. The drug 2141-V11 attaches to a protein on immune cells and activates the immune system to find and kill bladder cancer cells. It is given directly into the bladder through a catheter (flexible tube).
Leiomyosarcoma is a type of cancer that forms in smooth muscle. Researchers want to see if adding ADI-PEG 20 to the usual chemotherapy for leiomyosarcoma works better than chemotherapy alone. The people in this study have leiomyosarcoma that keeps growing despite treatment.
Researchers want to see how well enfortumab vedotin works in people with adenoid cystic carcinoma. This cancer most often starts in the salivary glands and certain other glands in the body. The people in this study have adenoid cystic cancer that came back or spread after treatment.
Researchers want to see how well reparixin works against myelofibrosis. This disease is a rare bone marrow cancer that disrupts your body's normal blood cell production.
Researchers want to find the best dose of ziftomenib to give with imatinib in people with advanced gastrointestinal stromal tumors (GIST). The people in this study have GIST that keeps growing after treatment.
Researchers are studying combining RMC-6236 with other anti-cancer drugs in people with advanced digestive cancers (pancreatic, colorectal cancer, and others). The people in this study have either:
Researchers want to find the best dose of ADCE-D01 to treat soft tissue sarcoma. In this study, we treat people with soft tissue sarcoma that is inoperable (cannot be surgically removed) or metastasized (spread).
Researchers want to see how well datopotamab deruxtecan (Dato-DXd) works alone and with other drugs against cancer. The people in this study have endometrial, ovarian, or urothelial cancer that has metastasized (spread).
Researchers want to learn if L19IL2 and L19TNF, alone or together, work well to treat melanoma when given with pembrolizumab. The people in this study have melanoma that has metastasized (spread) or is inoperable (cannot be taken out with surgery). Their cancers keep growing even after having immune-boosting therapy.
